Ayurcann Holdings Corp. (CSE: AYUR) (the " Company " or " Ayurcann "), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce its newly formed Advisory Board consisting of cannabis and non-cannabis sector professionals, who will provide guidance relating to the Company's strategic plans and initiatives, and highlight potential key areas of opportunity within the industry.

Igal Sudman, CEO of Ayurcann, commented: "We are thrilled to be officially launching the Ayurcann Advisory Board. The Executive Team has taken several months carefully selecting this group of top professionals who each bring unique strengths and backgrounds to the Company. We are proud to say that we have selected these individuals as our inaugural members."

Advisory Board Members include :

Michael Ash
Michael is the current CEO of Juno OTC Pharmaceuticals, an innovative private label supplier of DiN and NPN products to the Canadian market. Michael has held various high-profile positions in the pharmaceutical industry, notably serving as President of both Pharmetics and NutraLab Canada Ltd., where he developed and launched private label brands of vitamins, minerals and supplements for large retailers across the country. Michael also has extensive experience in Sales and Marketing roles where he has been able to build strong retail relationships across Canada.

Barry Katzman
Mr. Katzman is an accomplished senior executive and entrepreneur with a strong background in both the alcohol and cannabis sectors that includes leadership positions at Molson, as well as ownership roles at six different wineries including Creekside and Stoney Ridge Estates. Barry is the current Board Chairman and Executive director at Thrive Cannabis, Grey Beard Cannabis Co., and the CEO of Hemp Energy Drink. Mr. Katzman has been recognized on numerous occasions with awards for business development and philanthropic efforts in the Niagara region. He holds a business degree from Western University and an MBA from Niagara University in New York.

Trina Fraser
Trina is a partner at Brazeau Seller Law and head of BSL's CannaLaw® group, Trina has emerged as a leading practitioner in cannabis law in Canada and is often called upon for comment and opinion. Since 2019, the Chambers Canada guide has ranked Trina as a Band 1 lawyer in Cannabis Law. She was selected by her peers for inclusion in The Best Lawyers™ in Canada in 2020 and 2021 in the field of Cannabis Law. In 2019, she was named by Canadian Lawyer Magazine as one of the Top 25 Most Influential lawyers in Canada, and Trina was named "Attorney of the Year" at the 2019 O'Cannabiz Industry Awards Gala.

Iris Bincovich
Mrs. Iris Bincovich is the CEO of Innocan Pharma and an experienced C-level executive in healthcare and biotech, with a proven track record in taking companies public, raising capital, and increasing shareholder value. Iris has extensive experience in developing global business strategies to open and penetrate new markets. With nearly 20 years of international marketing, business development and sales experience, she has led and managed hundreds of successful international transactions in the OTC, cosmetics, and dermatology sectors.

Casey Hiltemann
Casey Hiltemann is the Founder and CEO of Budtenders Associate, an inclusive network working towards cannabis de-stigmatization and positive change through education, professional development, data, and research. Casey is also the co-founder of The Budtender's Choice Awards, an annual event acknowledging and bringing the industry together to recognize and celebrate excellence in Budtending, Customer Service, Retail Design, Branding, Cultivation and Extraction.

Ben Feferman
Ben is the CEO of Amuka Esports, one of Canada's leaders in the esports and gaming industry.  Mr. Feferman began his career in the cannabis industry organising large-scale meetups for industry participants, and now Ben works with several leading cannabis brands to help them reach the coveted gamer demographic.

Sudman continued, "As a public company that is solidifying itself as a long-standing player in the Canadian cannabis industry, the team and I wanted to develop an advisory group of individuals who we felt could provide their respective insights in parallel with the deployment of our strategies for brand asset growth and expansion. We look forward to working closely with this group and will continue to evaluate additional member candidates as our growth trajectory progresses."

For further information, please contact:
Igal Sudman, Chairman and Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322 x30
Email: igal@Ayurcann.com

Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: ir@Ayurcann.com

About Ayurcann Holdings Corp.
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company's expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company's facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize.   Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company's business, financial condition and/or results of operations.  The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.